Granisetron Labormed

Granisetron Labormed is a prescription oral medication that contains the active ingredient granisetron, a selective 5‑HT3 receptor antagonist. While the specific strength and dosage form are not disclosed, the product is marketed within the European Union and belongs to the antiemetic therapeutic class. It is used under medical supervision to help manage nausea and vomiting associated with certain medical procedures and improve patient comfort during treatment.

Granisetron Labormed is indicated for the prevention of nausea and vomiting in specific clinical settings.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV). - Prevention of postoperative nausea and vomiting (PONV). - Adjunct therapy for radiation‑induced nausea. - Use in patients receiving highly emetogenic chemotherapy. - May be considered when other antiemetics are insufficient.

The safety profile of granisetron includes both common and less frequent adverse events.

Common: - Headache. - Constipation. - Diarrhea. - Fatigue. - Dizziness.

Serious: - Severe allergic reaction (anaphylaxis). - Cardiac arrhythmia. - Prolonged QT interval. - Serotonin syndrome (rare).

When prescribing Granisetron Labormed, clinicians should evaluate several precautionary factors to ensure safe use.

- Assess cardiac history, especially QT prolongation risk. - Use caution in patients with electrolyte disturbances (e.g., low potassium or magnesium). - Evaluate for known hypersensitivity to granisetron or other 5‑HT3 antagonists. - Consider renal or hepatic impairment when dosing. - Avoid use during pregnancy unless benefit outweighs risk. - Monitor for signs of serotonin syndrome if combined with serotonergic agents.

Granisetron may interact with other medications; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concurrent use with other 5‑HT3 antagonists (e.g., ondansetron) due to additive effects. - Co‑administration with drugs that significantly prolong QT interval (e.g., certain antiarrhythmics, antipsychotics).

Use with caution: - Serotonergic agents such as SSRIs, SNRIs, tramadol, or linezolid. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase granisetron levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce effectiveness.